Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 1, 2010, Pages 124-130

  Agool, Ali ^a,d   Slart, Riemer H J A ^a   Dierckx, Rudi A J O ^a   Kluin, Philip M ^a   Visser, Lydia ^a   Jager, Pieter L ^b   Vellenga, Edo ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d TWENTEBORG HOSPITAL   (Netherlands)

Author keywords

Disease activity; Multiple myeloma; Somatostatin receptor scintigraphy

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; THALIDOMIDE;

ADULT; AGED; ARTICLE; BONE CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; PLASMACYTOMA; WHOLE BODY IMAGING; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN;

EID: 72949103457     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1199-5     Document Type: Article

References (12)

1. A Smith F Wisloff D Samson UK Myeloma Forum Nordic Myeloma Study Group British Committee for Standards in Haematology 2006 Guidelines on the diagnosis and management of multiple myeloma 2005 Br J Haematol 132 410 451 10.1111/j.1365-2141.2005.05867.x 16412016
2. BG Durie AD Waxman A D'Agnolo CM Williams 2002 Whole-body (18)F-FDG PET identifies high-risk myeloma J Nucl Med 43 1457 1463 12411548
3. MA Bredella L Steinbach G Caputo G Segall R Hawkins 2005 Value of FDG PET in the assessment of patients with multiple myeloma AJR Am J Roentgenol 184 1199 1204 15788594
4. P Georgii-Hemming T Strömberg ET Janson M Stridsberg HJ Wiklund K Nilsson 1999 The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines Blood 93 1724 1731 1:CAS:528:DyaK1MXhsFeqsrg%3D 10029602
5. EP Krenning DJ Kwekkeboom WH Bakker WA Breeman PPM Kooij HY Oei, et al. 1993 Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients Eur J Nucl Med 20 716 731 10.1007/BF00181765 1:STN:280:DyaK2c%2FgvFWjug%3D%3D 8404961
6. M de Jong WA Breeman WH Bakker PP Kooij BF Bernard LJ Hofland TJ Visser A Srinivasan MA Schmidt JL Erion JE Bugaj HR Macke EP Krenning 1998 Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy Cancer Res 58 437 441 9458086
7. P Sonneveld B van der Holt CM Segeren E Vellenga AJ Croockewit GE Verhoef JJ Cornelissen MR Schaafsma MH van Oers PW Wijermans PH Westveer HM Lokhorst Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) 2007 Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial Haematologica 92 928 935 10.3324/haematol.11168 1:CAS:528:DC%2BD2sXhtFGqu7vM 17606443 (Pubitemid 350144239)
8. HM Lokhorst I Schmidt-Wolf P Sonneveld B van der Holt H Martin R Barge U Bertsch J Schlenzka GM Bos S Croockewit S Zweegman I Breitkreuz P Joosten C Scheid M van Marwijk-Kooy HJ Salwender MH van Oers R Schaafsma R Naumann H Sinnige I Blau M Delforge O de Weerdt P Wijermans S Wittebol U Duersen E Vellenga H Goldschmidt Dutch-Belgian HOVON German GMMG 2008 Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma Haematologica 93 124 127 10.3324/haematol.11644 1:CAS:528:DC%2BD1cXitVOhsL4%3D 18166796 (Pubitemid 351156161)
9. S Hovenga SM Daenen JT de Wolf GW van Imhoff HC Kluin-Nelemans WJ Sluiter E Vellenga 2005 Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study Ann Hematol 84 311 316 10.1007/s00277-004-0981-5 1:CAS:528:DC%2BD2MXivVKhsro%3D 15605244 (Pubitemid 41166825)
10. A Mele M Offidani G Visani M Marconi F Cambioli M Nonni M Catarini E Brianzoni A Berbellini G Ascoli M Brunori V Agostini L Corvatta A Isidori A Spinelli M Gradari P Leoni 2007 Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans Br J Haematol 136 729 735 10.1111/j.1365-2141.2006.06489.x 1:CAS:528:DC%2BD2sXjvFWmtbk%3D 17233770 (Pubitemid 46246307)
11. B Fallahi M Saghari A Fard Esfahani M Eftekhari M Iravani D Beiki VR Dabbagh Kakhki R Sadeghi 2005 The value of 99mTc-MIBI whole body scintigraphy in active and in remission multiple myeloma Hell J Nucl Med 8 165 168
12. R Fonti B Salvatore M Quarantelli C Sirignano S Segreto F Petruzziello L Catalano R Liuzzi B Rotoli S Del Vecchio L Pace M Salvatore 2008 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma J Nucl Med 49 195 200 10.2967/jnumed.107.045641 18199607 (Pubitemid 351225656)